title: Management of osteoporosis and menopausal symptoms: focus on bazedoxifene/conjugated estrogen combination.
abstract: Loss of estrogen production in women during menopause results in a state of estrogen deficiency which has been associated with multiple problems, including vasomotor symptoms, symptoms of vulvovaginal atrophy, bone loss, and difficulties with sleep, mood, memory, and sexual activity. The only treatment option currently available to address multiple postmenopausal symptoms in women with an intact uterus is estrogen/progestin-containing hormone therapy (HT). Concerns surrounding side effects and published data regarding the association of HT with the increased risk for breast cancer have induced a decrease in the number of women seeking, initiating, and continuing this type of therapy. A combination containing bazedoxifene and conjugated estrogens (BZA/CE) maintains the established benefits of estrogen therapy for treatment of postmenopausal vasomotor symptoms, vulvovaginal atrophy, and osteoporosis, while certain estrogenic effects, such as stimulation of the uterus and breast, are antagonized without the side effects associated with HT. BZA/CE has been evaluated in a series of multicenter, randomized, double-blind, placebo-controlled, and active-controlled Phase III trials known as the Selective estrogens, Menopause, And Response to Therapy (SMART) trials. BZA/CE demonstrated clinically meaningful improvements in vasomotor symptoms, vulvovaginal atrophy, and a protective effect on the skeleton. These clinical benefits were associated with an acceptable safety profile and an improved tolerability compared with HT. BZA/CE showed a favorable safety profile on the breast, endometrium, and ovaries. The incidence of venous thromboembolism was low and the risk does not appear to be any greater than for CE alone or BZA alone or greater than HT. The incidence of coronary heart disease and cerebrovascular accidents were similar to placebo. The overall incidence of cancer (including breast cancer) was low and similar to placebo. The SMART trials demonstrate that BZA/CE is an alternative option for treating non-hysterectomized, symptomatic, postmenopausal women.
authors: Pfizer Inc, Collegeville, PA, Columbia University Medical Center, New York, NY, USA.
authors: Sebastian
authors: S
authors: Mirkin
authors: James H
authors: JH
authors: Pickar
keywords: bazedoxifene; conjugated estrogens; menopause; osteoporosis; tissue selective estrogen complex; vasomotor symptoms
references: Fertil Steril. 2001 Jul;76(1):13-24
references: 11438314
references: Maturitas. 2009 Aug 20;63(4):329-35
references: 19647382
references: Obstet Gynecol. 2000 Sep;96(3):351-8
references: 10960625
references: Drugs Aging. 2010 Jul 1;27(7):533-44
references: 20583848
references: J Natl Cancer Inst. 2010 Jun 16;102(12):843-5
references: 20530764
references: Fertil Steril. 2009 Sep;92(3):1025-1038
references: 19635615
references: Menopause. 2012 Mar;19(3):278-82
references: 21997498
references: Menopause. 2009 Nov-Dec;16(6):1116-24
references: 19546826
references: J Clin Oncol. 1997 Oct;15(10):3201-7
references: 9336356
references: Br J Obstet Gynaecol. 1994 Aug;101(8):661-2
references: 7947498
references: Eur J Obstet Gynecol Reprod Biol. 1996 Apr;64 Suppl:S21-4
references: 8732469
references: Menopause. 2010 Mar;17(2):281-9
references: 19779382
references: Fertil Steril. 2009 Sep;92(3):1039-1044
references: 19635614
references: Climacteric. 2010 Jun;13(3):210-8
references: 20184423
references: Fam Pract. 2001 Apr;18(2):189-94
references: 11264270
references: Reprod Sci. 2008 Dec;15(10):984-92
references: 19088368
references: Breast Cancer Res Treat. 2012 Feb;132(1):275-85
references: 22042371
references: Ann Intern Med. 2004 Feb 3;140(3):184-8
references: 14757616
references: Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002978
references: 15495039
references: Am J Epidemiol. 2000 Sep 1;152(5):463-73
references: 10981461
references: JAMA. 2003 Jun 25;289(24):3243-53
references: 12824205
references: J Clin Oncol. 2010 Aug 20;28(24):3830-7
references: 20644098
references: Curr Med Res Opin. 2009 Nov;25(11):2689-98
references: 19775194
references: Menopause. 2012 Mar;19(3):302-10
references: 22105149
references: Fertil Steril. 2009 Sep;92(3):1018-1024
references: 19635613